Amgen (AMGN) Stock: $300M Puerto Rico Facility Expansion Announced

Table of Contents Amgen (AMGN) shares dropped 1.54% on Monday following the biotechnology company’s announcement of a new $300 million capital commitment to enhance its biologics production facility located in Juncos, Puerto Rico. Amgen Inc., AMGN The capital infusion aims to increase manufacturing throughput and implement cutting-edge production technologies at the Puerto Rico location, which has been operational for over three decades since its 1992 launch. Currently, the Juncos manufacturing site supplies biologic therapeutics to more than 60 international markets. The new funding will fortify existing manufacturing positions while generating hundreds of temporary construction opportunities. Chief Executive Officer Robert Bradway characterized the expansion as evidence of Amgen’s “ongoing dedication to U.S.-based manufacturing” and emphasized its role in securing domestic pharmaceutical supply chains and ensuring uninterrupted patient medicine access. Puerto Rico’s Governor Jenniffer González Colón praised the development, noting that the investment validates the effectiveness of policies designed to bolster the island’s biopharmaceutical industry. The newly announced $300 million supplements the $650 million Amgen had previously earmarked for Puerto Rico operations over the preceding year, which was projected to generate approximately 750 employment opportunities. This Puerto Rico expansion represents one component of a comprehensive U.S. manufacturing initiative. Throughout the past year, Amgen has pledged $900 million toward Ohio facilities, allocated $600 million for a California-based science and innovation hub, and committed over $1.5 billion to North Carolina operations. When combined with the latest Puerto Rico announcement, Amgen’s recent domestic manufacturing pledges exceed $3.65 billion in total value. Since the 2017 Tax Cuts and Jobs Act took effect, Amgen reports having deployed more than $40 billion toward manufacturing infrastructure and research and development initiatives. The investment announcement arrives amid escalating pressure from the Trump administration targeting pharmaceutical companies regarding drug imports. In April, President Trump enacted an executive order establishing 100% tariff rates on branded pharmaceutical products entering the United States, unless manufacturers reached government pricing agreements or pledged to establish domestic production capabilities. Amgen’s strengthened U.S. manufacturing presence enables the company to better manage these regulatory challenges, though company officials portrayed the Puerto Rico investment as aligned with broader long-term supply chain objectives. As a U.S. territory, Puerto Rico has served as a pharmaceutical manufacturing center for more than six decades and hosts numerous major pharmaceutical company operations. The Juncos facility has functioned as part of Amgen’s production network since 1992 and serves as a critical component of the company’s worldwide biologics distribution system. Amgen has not disclosed a definitive completion date for the Puerto Rico facility expansion project.